secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK:        0000879407
Form:       8-K
Filed at:   2026-08-04T20:03:02+00:00
Accession:  0000879407-26-000058
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arrowhead Q3 revenue $75.3M; plozasiran Phase 3 hits endpoints; Madrigal license deal
--------------------------------------------------------------------------------

- Revenue $75.3M (up 171% YoY); net loss $194.3M ($1.36 diluted EPS) vs $175.2M ($1.26) prior year.
- Plozasiran Phase 3 SHASTA-3/4: 79% and 81% median triglyceride reductions; 78% reduction in acute pancreatitis events.
- Acquired FDA priority review voucher for plozasiran sNDA in sHTG, expected before end of 2026.
- Exclusive license to Madrigal for ARO-PNPLA3: $25M upfront, up to $975M milestones, tiered royalties.
- REDEMPLO prescriptions roughly doubled in Q3; >400 prescribers; EU and Australia marketing authorizations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879407/000087940726000058/0000879407-26-000058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879407/000087940726000058/arwr-20260804.htm
  HTML page:      https://secwatch.observer/filing/0000879407-26-000058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer